This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07881757 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Pfizer |
| Enrollment | 258 participants |
| Design | Not stated |
| Conditions | Obstructive sleep apnea; Overweight or obesity |
| Interventions | Berobenatide; Placebo |
| Start | Oct 19, 2026 |
| Primary completion | Jun 1, 2028 |
| Study completion | Not stated |
| Results posted | Not yet |
| Registry last updated | Not stated |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). See the trial changes feed for what has changed recently.
More from Pfizer
- Once-monthly berobenatide in Chinese adults (Phase 3) (Phase 3 NCT07874633)
- VESPER-JW: once-weekly berobenatide in Japan (Phase 3 NCT07794761)
- VESPER-SWITCH: monthly berobenatide for weight maintenance (Phase 3 NCT07845500)
- VESPER-JM: once-monthly berobenatide in Japan (Phase 3 NCT07794774)
Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.